Trial Profile
A Phase II, Multi-Center, Open-Label Study of Tremelimumab Monotherapy in Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Jun 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Bladder cancer; Pancreatic cancer; Solid tumours; Triple negative breast cancer
- Focus Therapeutic Use
- Acronyms Tremelimumab_CTLA4_Basket
- Sponsors AstraZeneca; AstraZeneca AB
- 19 Apr 2023 Status changed from active, no longer recruiting to completed.
- 20 Jan 2023 Planned End Date changed from 30 Dec 2022 to 29 Dec 2023.
- 25 Nov 2021 Planned End Date changed from 31 Dec 2021 to 30 Dec 2022.